Document 0279
 DOCN  M9460279
 TI    Human immunodeficiency virus infection in pregnancy: epidemiology and
       prevention of vertical transmission.
 DT    9404
 AU    Craven DE; Steger KA; Jarek C; Department of Medicine, Boston University
       School of Medicine, MA.
 SO    Infect Control Hosp Epidemiol. 1994 Jan;15(1):36-47. Unique Identifier :
       AIDSLINE MED/94179749
 AB    The preponderance of AIDS cases in women during their reproductive years
       demands attention to primary prevention, early recognition, and
       appropriate interventions. Increases in the epidemic among injection
       drug users and heterosexually exposed persons have resulted in an
       increased impact of HIV/AIDS among women and children. It is clear that
       vertical transmission of HIV can occur early in pregnancy, during labor
       and delivery, or in the postpartum period. For these reasons, prevention
       strategies must be comprehensive and include primary prevention and
       appropriate intervention during pregnancy and in the peripartum and
       postpartum area. Stringent infection control techniques are imperative
       during delivery and in the postpartum period, even in the absence of
       clear data supporting this intervention. Recent data suggest that the
       cost of treating one adult patient with AIDS is approximately $100,000,
       making prevention and intervention imperative.
 DE    Adult  AIDS Serodiagnosis  Breast Feeding  Female  Fetal
       Diseases/BLOOD/DRUG THERAPY/*EPIDEMIOLOGY/*PREVENTION &  CONTROL  Human
       HIV Infections/BLOOD/DRUG THERAPY/*EPIDEMIOLOGY/*PREVENTION &
       CONTROL/TRANSMISSION  Immunoglobulins, Intravenous/THERAPEUTIC USE
       Infant  Infant, Newborn  Labor Complications/BLOOD/DRUG
       THERAPY/*EPIDEMIOLOGY/*PREVENTION  & CONTROL  Patient Education
       Pregnancy  Pregnancy Complications, Infectious/BLOOD/DRUG THERAPY/
       *EPIDEMIOLOGY/*PREVENTION & CONTROL  Primary Prevention  Puerperal
       Disorders/BLOOD/DRUG THERAPY/*EPIDEMIOLOGY/*PREVENTION  & CONTROL  Risk
       Factors  Zidovudine/THERAPEUTIC USE  JOURNAL ARTICLE  REVIEW  REVIEW,
       MULTICASE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).